Sanli O, Zorba O U, Erdem S, Tezer M, Kilicar-Slan I, Esen T, Tunc M
Departments of Urology and Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Minerva Urol Nefrol. 2010 Dec;62(4):347-53.
The aim of this study was to investigate the significance of microscopic venous invasion (MVI) as a prognostic factor for patients with renal cell carcinoma (RCC).
The present study included 220 patients with non-metastatic RCC who underwent radical nephrectomy (RN). MVI was defined by the presence of a cancer cell in blood vessels based on microscopic examination of hematoxylin-eosin stained specimens. The impact of MVI on disease progression and survival after 37 (6-190) months of median follow-up and its correlation with known clinicopathological features were studied. Survival analyses using Kaplan-Meier and log-rank models for univariate comparisons and Cox proportional hazards model for multivariate analyses were performed.
MVI was found in 68 patients (30.8%), and of these, 26 (38.2%) developed a tumor recurrence and 16 (23.5%) died of cancer progression, whereas only 18 (11.8%) of the remaining 152 patients without MVI presented with disease-recurrence and 8 (5.3%) died of cancer. In the multivariate analysis, MVI (P=0.014) Fuhrman's grade (P=0.028), and sarcomatoid differentiation (SD) (P=0.01) were the factors predicted a decreased disease-free survival (DFS). Meanwhile, MVI (P=0.04) and SD (P=0.029) were also found to be predictor of cancer specific survival (CSS) with necrosis (P=0.037) in multivariate analysis.
The present study showed that MVI is associated with the vast majority of the adverse pathological features related with RCC. Furthermore, it was found to be an independent clinical prognostic factor for DFS and CSS.
本研究旨在探讨微小静脉侵犯(MVI)作为肾细胞癌(RCC)患者预后因素的意义。
本研究纳入220例行根治性肾切除术(RN)的非转移性RCC患者。MVI通过苏木精-伊红染色标本的显微镜检查确定血管内存在癌细胞来定义。研究了MVI对中位随访37(6 - 190)个月后疾病进展和生存的影响及其与已知临床病理特征的相关性。采用Kaplan-Meier法和对数秩检验进行单因素生存分析比较,采用Cox比例风险模型进行多因素分析。
68例患者(30.8%)发现有MVI,其中26例(38.2%)发生肿瘤复发,16例(23.5%)死于癌症进展,而其余152例无MVI的患者中只有18例(11.8%)出现疾病复发,8例(5.3%)死于癌症。多因素分析中,MVI(P = 0.014)、Fuhrman分级(P = 0.028)和肉瘤样分化(SD)(P = 0.01)是预测无病生存期(DFS)降低的因素。同时,多因素分析中MVI(P = 0.04)和SD(P = 0.029)也是癌症特异性生存(CSS)的预测因素,坏死(P = 0.037)也与之相关。
本研究表明,MVI与绝大多数与RCC相关的不良病理特征有关。此外,它被发现是DFS和CSS的独立临床预后因素。